[EN] ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE EN TANT QU'INHIBITEURS DE CANAL SODIQUE POUR LE TRAITEMENT DE LA DOULEUR
申请人:AMGEN INC
公开号:WO2011103196A1
公开(公告)日:2011-08-25
The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
[EN] SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS<br/>[FR] N-[2-(4-PHÉNOXYPIPÉRIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ÉTHYL]BENZAMIDE SUBSTITUÉ ET DÉRIVÉS DE N-[2-(4-BENZYLOXYPIPÉRIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ÉTHYL]BENZAMIDE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
申请人:AXXAM SPA
公开号:WO2018041563A1
公开(公告)日:2018-03-08
The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS
申请人:Bregman Howard
公开号:US20130131035A1
公开(公告)日:2013-05-23
The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
From dopamine 4 to sigma 1: Synthesis, SAR and biological characterization of a piperidine scaffold of σ1 modulators
作者:Kirsten T. Tolentino、Viktoriya Mashinson、Manish K. Sharma、Yashpal S. Chhonker、Daryl J. Murry、Corey R. Hopkins
DOI:10.1016/j.ejmech.2022.114840
日期:2022.12
The sigma 1 receptor is a multifunctional receptor with wide distribution in the nervous system and its function has been implicated with a number of neurological disorders including dementia and Alzheimer's disease (AD) and other neurodegenerative disorders. In addition, modulators of σ1 have been advanced into clinical trials for the treatment of pain. Starting from our previously disclosed piperidine
σ1 受体是一种广泛分布于神经系统的多功能受体,其功能与许多神经系统疾病有关,包括痴呆和阿尔茨海默氏病 (AD) 以及其他神经退行性疾病。此外,σ1 调节剂已进入治疗疼痛的临床试验。从我们之前公开的哌啶支架开始,我们已经确定了一类有效的 sigma 1 调节剂。这项工作突出了导致 D 4和 σ1 活动差异的关键 SAR 组件。此外,我们进一步分析了一组体外和体内的脱靶受体中的先导化合物药代动力学研究。这最终导致发现了多种 σ1 受体调节剂,这些调节剂具有允许在动物模型中进行研究的特性。